Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings Inc (INFU) delivers essential medical equipment and outpatient care services across North America, specializing in infusion therapy solutions for oncology, pain management, and chronic care. This page provides investors and healthcare professionals with timely updates on the company's operational milestones and strategic initiatives.
Access consolidated INFU news including earnings announcements, regulatory filings, and partnership developments. Our repository features press releases related to medical device innovations, service expansions, and leadership updates – all critical for assessing the company's position in the durable medical equipment sector.
Key content categories include quarterly financial results, biomedical service enhancements, and coverage of INFU's dual-platform strategy balancing patient care with device lifecycle management. Bookmark this page to monitor INFU's progress in bridging clinical and home-based healthcare delivery.
InfuSystem Holdings reported Q2 2022 net revenues of $27 million, marking a 9% increase year-over-year. Integrated Therapy Services (ITS) revenues grew 6% to $17.2 million, while Durable Medical Equipment (DME) revenues surged 15% to $9.8 million. Despite revenue growth, gross profit fell 1% to $14.9 million with a gross margin decline to 55.1%. The company posted a net loss of $0.2 million or $(0.01) per diluted share. Adjusted EBITDA was $5.5 million, a 6% decrease. Full-year revenue guidance was revised to 10%-13% growth.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced the release of its second quarter 2022 financial results on August 4, 2022, before market opening. A subsequent conference call will be held at 9:00 a.m. Eastern Time on the same day to discuss these results. InfuSystem specializes in outpatient care services for durable medical equipment, operating two main platforms: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME). Services include oncology, pain management, and more.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national sales and marketing agreement with Ventis Pharma for its Endura-Kit™, a patented local anesthetic compound. This collaboration aims to enhance pain management solutions, focusing on opioid alternatives through multi-modal approaches. The Endura-Kit™ combines three non-opioid drugs, designed to improve post-operative and chronic pain management effectively. This partnership is expected to expand InfuSystem's revenue streams and enhance their service offerings.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced that its CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will participate in the Craig-Hallum's 19th Annual Institutional Investor Conference on June 1, 2022. This event will be held virtually, and management will conduct one-on-one meetings throughout the day. Interested investors can reach out to Craig-Hallum or contact Lytham Partners at 602-889-9700 or via email at infu@lythampartners.com. InfuSystem is a national healthcare service provider, specializing in outpatient care for durable medical equipment.
InfuSystem Holdings, Inc. (NYSE: INFU) announced a 9% revenue increase for Q1 2022, totaling $26.8 million. Growth was driven by a 5% rise in Integrated Therapy Services and an 18% rise in Durable Medical Equipment Services. Although gross profit rose to $15.4 million, the gross margin decreased to 57.4%. InfuSystem signed a three-year Master Service Agreement with a leading medical technology company, potentially generating $10-12 million in annual revenue. Operating cash flow surged 54% to $4.1 million, but a net loss of $0.4 million was reported. The company expects 15-20% revenue growth for the full year.
InfuSystem Holdings, Inc. (NYSE American: INFU) has secured a three-year master service agreement with a leading global healthcare technology company, effective April 25, 2022. This agreement involves providing maintenance and repair services for over 300,000 infusion pumps across more than 1,200 medical facilities in North America. The estimated annual revenue from this contract is between $10 million and $12 million. The CEO emphasizes this partnership as a foundation for growth in their Durable Medical Equipment (DME) services segment.
InfuSystem Holdings, Inc. (NYSE American: INFU) will release its first quarter 2022 financial results on
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national distribution agreement with Solo-Dex, Inc. for its continuous nerve block catheters, enhancing acute pain management capabilities. This technology allows anesthesiologists to insert catheters in two to three minutes for major procedures, potentially improving patient recovery while reducing reliance on opioids. The collaboration is aimed at capturing a significantly larger market, estimated to be ten times the current nerve catheter market. The joint effort aims to establish a new standard of care in pain management.
InfuSystem Holdings reported financial results for 2021, with net revenues at $102.4 million, a 5% increase from 2020. The fourth quarter saw revenues of $26.5 million, up 7.3% year-over-year. Despite this growth, net income dropped to $0.4 million, significantly lower than $10.7 million in Q4 2020. The gross margin decreased to 57.7%. Management anticipates 20% revenue growth in 2022, driven by pain management and a pending biomedical services contract expected to add $8-$12 million in revenue.
InfuSystem Holdings (NYSE: INFU) will announce preliminary fourth quarter and full year 2021 financial results on February 10, 2022, before the market opens. A conference call will follow the announcement at 9:00 a.m. Eastern Time to discuss these results. The company specializes in facilitating outpatient care for durable medical equipment through its Integrated Therapy Services and Durable Medical Equipment Services platforms. Interested parties can participate via phone or listen through a live webcast on the company’s investor relations website.
FAQ
What is the current stock price of Infusystem Hld (INFU)?
What is the market cap of Infusystem Hld (INFU)?
